title: Ocular side effects of biological agents in oncology: what should the clinician be aware of?
abstract: During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: "name of biological agent (both generic and commercial names)" AND "eye" OR "ocular". If we found a side effect that has been associated with a drug, we researched Medline using the following search string: "name of biological agent" (both generic and commercial names) AND "term for the specific side effect". Due to the wealth of material we report only the drugs that are approved by the FDA.
authors.affiliation: Department of Ophthalmology, Universitätsklinikum des Saarlandes, Homburg, Germany.
authors.forename: Tobias
authors.initials: T
authors.lastname: Hager
authors.affiliation: Department of Ophthalmology, Universitätsklinikum des Saarlandes, Homburg, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Seitz
keywords: EGFR; biological; interferon; ocular side effect; targeted therapy